Cathy Cantalloube

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Venues

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Joaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve, Jean-Jacques Grob, Oliver Bechter, Maria Vieito, Maria Jose de Miguel, Dirk Schadendorf, Melissa Johnson, Clemence Pouzin, Cathy Cantalloube, Rui Wang, Jooyun Lee, Xiaofei Chen, Brigitte Demers, Amele Amrate, Giovanni Abbadessa, F Stephen Hodi
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study. Clinical and translational science 17 (6) (2024)
Joaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve, Jean-Jacques Grob, Oliver Bechter, Maria Vieito, Maria Jose de Miguel, Dirk Schadendorf, Melissa Johnson, Clemence Pouzin, Cathy Cantalloube, Rui Wang, Jooyun Lee, Xiaofei Chen, Brigitte Demers, Amele Amrate, Giovanni Abbadessa, F Stephen Hodi
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study. Clinical and translational science 17 (6) (2024)
Joaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve, Jean-Jacques Grob, Oliver Bechter, Maria Vieito, Maria Jose de Miguel, Dirk Schadendorf, Melissa Johnson, Clemence Pouzin, Cathy Cantalloube, Rui Wang, Jooyun Lee, Xiaofei Chen, Brigitte Demers, Amele Amrate, Giovanni Abbadessa, F Stephen Hodi
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study. Clinical and translational science 17 (6) (2024)
Joaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve, Jean-Jacques Grob, Oliver Bechter, Maria Vieito, Maria Jose de Miguel, Dirk Schadendorf, Melissa Johnson, Clemence Pouzin, Cathy Cantalloube, Rui Wang, Jooyun Lee, Xiaofei Chen, Brigitte Demers, Amele Amrate, Giovanni Abbadessa, F Stephen Hodi
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study. Clinical and translational science 17 (6) (2024)

Cathy Cantalloube.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Cathy Cantalloube